Year: 2016
New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance
December 8, 2016
Presentation at San Antonio Breast Cancer Symposium 2016 Bergen, Norway, December 8, 2016 – Leading…
Read MoreBerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
December 5, 2016
Long term disease stabilisation observed highlighting importance of AXL in NSCLC Bergen, Norway, November 29,…
Read MoreBerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at the ASH 2016
December 5, 2016
Bergen: Leading oncology biopharmaceutical company BerGenBio AS, today presented clinical and biological data from a…
Read MoreNew BGB324 study points to novel mechanism to enhance immunotherapy efficacy
September 26, 2016
Presented at CRI-CIMT-EATI-AACR - The 2nd International Cancer Immunotherapy Conference Bergen, Norway, September 25, 2016…
Read MoreBerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
July 4, 2016
Promising clinical activity with biologic activity, tolerability, and durability BerGenBio AS ("BerGenBio" or the "Company"),…
Read MoreBerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade
April 18, 2016
Bergen, Norway, April 18, 2016 – BerGenBio AS (“BerGenBio” or the “Company”) announces that preclinical…
Read More
